Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Bill Weldon gets new chairman title at Chase Bank

William Weldon, who last year stepped down at Johnson & Johnson after running the company for years, has again added the title of chairman to his resume. In what The Wall Street Journal characterized as a stealth move, Weldon has replaced James Dimon in that role. Weldon was already a top director on the Chase board.

Vivus president steps down, Bayer HealthCare gets new CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Amgen puts R&D chief in charge at newly-acquired Onyx

After closing on its $10 billion Onyx buyout earlier in the week, Amgen has now promoted R&D chief Pablo Cagnoni to the president's office. Cagnoni was only hired back in March but gets about a $3.8 million payday in the deal.

UPDATED: Struggling Merck slashing 8,500 jobs in major R&D, commercial reorganization

The pharma giant said that it will reorganize its R&D and commercial operations to narrow and sharpen its development focus and carve out $2.5 billion in annual expenses, eliminating a total of about 20% of its 81,000 staff jobs when these new cuts are added to existing restructuring plans.

Lundbeck's cost-saving reorg plan to claim up to 200 jobs

Supply-chain simplification and new procurement processes are also part of the plan.

Lundbeck to cull 200 staffers in cost-cutting drive

The pharma company expects to save about a half billion Danish kroner annually in the move.

Germany's Bayer taps Pfizer's Olivier Brandicourt to head Bayer HealthCare

Brandicourt will assume the top job at Bayer HealthCare Nov. 1, taking over the reins from executive Wolfgang Plischke, who has been running the unit while the company found a new leader.

Regado cuts workforce by 15% after IPO fizzle

A month after limping onto the biotech IPO scene with a slashed-price $47 million raise, Regado Biosciences is trimming about 15% of its staff, saving cash it'll need for a costly Phase III study.

Belén Garijo named Merck Serono CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Novartis board to shrink executive pay, director says

Novartis board member Pierre Landolt let a couple of things slip in an interview with the Basler Zeitung published over the weekend. The first is a bit of a head-scratcher: Landolt would like the new chairman of Novartis and Roche to get together for some exploratory merger talk.